Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Victoria Risbrough

    TitleProfessor In Residence
    SchoolUniversity of California, San Diego
    DepartmentPsychiatry
    Address9500 Gilman Drive #0804
    CA La Jolla 92093
    Phone619-543-2900
    vCardDownload vCard

      Collapse Overview 
      Collapse Overview

      Biography

      Dr. Risbrough received her B.A. degree in Psychology and her Ph.D. in Neuroscience from the University of California, San Diego. She joined as faculty in the Department of Psychiatry at UCSD in 2007 and became Associate Professor in 2012. She is the Associate Director of Neuroscience for the Center of Excellence for Stress and Mental Health at the San Diego Veterans Healthcare System. Dr. Risbrough is the Principal Investigator on awards from the National Institute of Mental Health, NARSAD, Veteran’s Affairs and the U.S. Department of Defense. She is also Director of the Neurocognition Project for the Marine Resiliency Study funded by Navy BUMED. She was the Guest Editor for the Special Issue on PTSD for Neuropharmacology and is an Associate Editor for a number of pharmacology journals. She is also a member of the Molecular Neuropharmacology and Signaling study section for NIH. Dr. Risbrough’s research is centered on translational mechanisms and treatments of anxiety disorders using preclinical and clinical approaches. Her primary focus is to identify mechanisms of risk and resilience to anxiety disorders, particularly posttraumatic stress disorder as well as development of new pharmacological treatments for these disorders. For example, she examines the contribution of corticotropin releasing factor to stress and anxiety responses using pharmacological and genetic techniques in mice. Her program also identifies genetic and environmental contributions to stress behavior and fear learning. For example she has recently been funded to examine the role of the COMTVal158Met polymorphism in PTSD risk and treatment response. By measuring physiological responses to stress (including heart rate and startle reactivity) in animal models and in clinic, her research develops translational probes of anxiety responding and treatment efficacy.

      Research Interests

      Dr. Risbrough’s research is centered on translational mechanisms and treatments of anxiety disorders using preclinical and clinical approaches. Her primary focus is understanding mechanisms of risk and resilience to anxiety disorders, particularly post-traumatic stress disorder. For example, she examines the contribution of corticotropin releasing factor to stress and anxiety responses using pharmacological and genetic techniques in mice. Her program also identifies genetic and environmental contributions to stress behavior and fear learning. By measuring physiological responses to stress (including heart rate and startle reactivity) in animal models and in clinic, her research develops translational probes of anxiety responding and treatment efficacy.

      Clinical Focus

      The goal of our work is to understand the basic mechanisms underlying anxiety and fear responses, as well as to identify biological factors contributing to the risk of and resilience to development of anxiety disorders. With this information we hope to develop better measures of treatment response in anxiety disorders and identify novel targets of pharmacotherapeutics.


      Collapse Research 
      Collapse Research Activities and Funding
      Role of COMTval158met in PTSD risk and treatment response
      NIH I01BX002558Oct 1, 2014 - Sep 30, 2018
      Role: Principal Investigator
      Understanding the Role of COMT Variants in Sensorimotor Gating
      NIH R33MH083499May 15, 2008 - Apr 30, 2012
      Role: Principal Investigator
      Understanding the Role of COMT Variants in Sensorimotor Gating
      NIH R21MH083499May 15, 2008 - Apr 30, 2010
      Role: Principal Investigator
      Murine model of CRF effects on fear extinction: relevance to PTSD
      NIH R21MH076850May 5, 2006 - Apr 30, 2009
      Role: Principal Investigator
      Stress and CRF System Effects on Information Processing
      NIH R01MH074697Jul 1, 2005 - Apr 30, 2015
      Role: Principal Investigator
      Role of CRF and 5-HT1A receptors in ASR
      NIH F31MH068133Apr 1, 2003 - Mar 31, 2005
      Role: Principal Investigator

      Collapse ORNG Applications 
      Collapse Websites

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Deslauriers J, van Wijngaarde M, Geyer MA, Powell S, Risbrough V. Effects of LPS-induced immune activation prior to trauma exposure on PTSD-like symptoms in mice. Behav Brain Res. 2017 Jan 31; 323:117-123. PMID: 28159589.
        View in: PubMed
      2. Ahmari SE, Risbrough V, Geyer MA, Simpson HB. Prepulse Inhibition Deficits in Obsessive-Compulsive Disorder are More Pronounced in Females. Neuropsychopharmacology. 2016 Dec; 41(13):2963-2964. PMID: 27818517.
        View in: PubMed
      3. Huang M, Harrington DL, Robb A, Angeles A, Nichols S, Drake AI, Song T, Diwakar M, Huang CW, Risbrough V, Dale AM, Bartsch H, Matthews S, Huang JW, Lee RR, Baker DG. Resting-state MEG Reveals Different Patterns of Aberrant Functional Connectivity in Combat-related Mild Traumatic Brain Injury. J Neurotrauma. 2016 Oct 20. PMID: 27762653.
        View in: PubMed
      4. Steinman SA, Ahmari SE, Choo T, Kimeldorf MB, Feit R, Loh S, Risbrough V, Geyer MA, Steinglass JE, Wall M, Schneier FR, Fyer AJ, Simpson HB. PREPULSE INHIBITION DEFICITS ONLY IN FEMALES WITH OBSESSIVE-COMPULSIVE DISORDER. Depress Anxiety. 2016 Mar; 33(3):238-46. PMID: 26878422.
        View in: PubMed
      5. Glenn DE, Acheson DT, Geyer MA, Nievergelt CM, Baker DG, Risbrough V. HIGH AND LOW THRESHOLD FOR STARTLE REACTIVITY ASSOCIATED WITH PTSD SYMPTOMS BUT NOT PTSD RISK: EVIDENCE FROM A PROSPECTIVE STUDY OF ACTIVE DUTY MARINES. Depress Anxiety. 2016 Mar; 33(3):192-202. PMID: 26878585.
        View in: PubMed
      6. Minassian A, Baker DG, Risbrough V. Heart Rate Variability and Posttraumatic Stress Disorder. JAMA Psychiatry. 2016 Feb 1; 73(2):178-9. PMID: 26720754.
        View in: PubMed
      7. Risbrough V, Glenn DE, Baker DG. On the Road to Translation for PTSD Treatment: Theoretical and Practical Considerations of the Use of Human Models of Conditioned Fear for Drug Development. Curr Top Behav Neurosci. 2016; 28:173-96. PMID: 27311760.
        View in: PubMed
      8. Toth M, Flandreau EI, Deslauriers J, Geyer MA, Mansuy IM, Merlo Pich E, Risbrough V. Overexpression of Forebrain CRH During Early Life Increases Trauma Susceptibility in Adulthood. Neuropsychopharmacology. 2016 May; 41(6):1681-90. PMID: 26538448.
        View in: PubMed
      9. Mandyam CD, Schilling JM, Cui W, Egawa J, Niesman IR, Kellerhals SE, Staples MC, Busija AR, Risbrough V, Posadas E, Grogman GC, Chang JW, Roth DM, Patel PM, Patel HH, Head BP. Neuron-Targeted Caveolin-1 Improves Molecular Signaling, Plasticity, and Behavior Dependent on the Hippocampus in Adult and Aged Mice. Biol Psychiatry. 2015 Oct 8. PMID: 26592463.
        View in: PubMed
      10. Minassian A, Maihofer AX, Baker DG, Nievergelt CM, Geyer MA, Risbrough V. Association of Predeployment Heart Rate Variability With Risk of Postdeployment Posttraumatic Stress Disorder in Active-Duty Marines. JAMA Psychiatry. 2015 Oct 1; 72(10):979-86. PMID: 26353072.
        View in: PubMed
      11. Acheson DT, Risbrough V. Oxytocin Enhancement of Fear Extinction: A New Target for Facilitating Exposure-Based Treatments? Biol Psychiatry. 2015 Aug 1; 78(3):154-5. PMID: 26143973.
        View in: PubMed
      12. Acheson DT, Eyler LT, Resovsky J, Tsan E, Risbrough V. Fear extinction memory performance in a sample of stable, euthymic patients with bipolar disorder. J Affect Disord. 2015 Oct 1; 185:230-8. PMID: 26247493.
        View in: PubMed
      13. Higa KK, Ji B, Buell MR, Risbrough V, Powell SB, Young JW, Geyer MA, Zhou X. Restoration of Sp4 in Forebrain GABAergic Neurons Rescues Hypersensitivity to Ketamine in Sp4 Hypomorphic Mice. Int J Neuropsychopharmacol. 2015; 18(11). PMID: 26037489.
        View in: PubMed
      14. Li X, Kaczanowska K, Finn MG, Markou A, Risbrough V. The GABAB receptor positive modulator BHF177 attenuated anxiety, but not conditioned fear, in rats. Neuropharmacology. 2015 Oct; 97:357-64. PMID: 26002628.
        View in: PubMed
      15. Norman SB, Haller M, Spadoni AD, Drummond SP, Risbrough V, Hamblen JL, Trim RS, Blanes EX. Maximizing the utility of a single site randomized controlled psychotherapy trial. Contemp Clin Trials. 2015 May; 42:244-51. PMID: 25933919.
        View in: PubMed
      16. Acheson DT, Feifel D, Kamenski M, Mckinney R, Risbrough V. Intranasal oxytocin administration prior to exposure therapy for arachnophobia impedes treatment response. Depress Anxiety. 2015 Jun; 32(6):400-7. PMID: 25826649.
        View in: PubMed
      17. Breen MS, Maihofer AX, Glatt SJ, Tylee DS, Chandler SD, Tsuang MT, Risbrough V, Baker DG, O'Connor DT, Nievergelt CM, Woelk CH. Gene networks specific for innate immunity define post-traumatic stress disorder. Mol Psychiatry. 2015 Mar 10. PMID: 25754082.
        View in: PubMed
      18. Yurgil KA, Clifford RE, Risbrough V, Geyer MA, Huang M, Barkauskas DA, Vasterling JJ, Baker DG. Prospective Associations Between Traumatic Brain Injury and Postdeployment Tinnitus in Active-Duty Marines. J Head Trauma Rehabil. 2015 Feb 19. PMID: 25699623.
        View in: PubMed
      19. Meyer MD, Risbrough V, Liang J, Boutelle KN. Pavlovian conditioning to hedonic food cues in overweight and lean individuals. Appetite. 2015 Apr; 87:56-61. PMID: 25526826.
        View in: PubMed
      20. Flandreau E, Risbrough V, Lu A, Ableitner M, Geyer MA, Holsboer F, Deussing JM. Cell type-specific modifications of corticotropin-releasing factor (CRF) and its type 1 receptor (CRF1) on startle behavior and sensorimotor gating. Psychoneuroendocrinology. 2015 Mar; 53:16-28. PMID: 25575243.
        View in: PubMed
      21. Boutelle KN, Liang J, Knatz S, Matheson B, Risbrough V, Strong D, Rhee KE, Craske MG, Zucker N, Bouton ME. Design and implementation of a study evaluating extinction processes to food cues in obese children: The Intervention for Regulations of Cues Trial (iROC). Contemp Clin Trials. 2015 Jan; 40:95-104. PMID: 25461494.
        View in: PubMed
      22. Acheson DT, Geyer MA, Baker DG, Nievergelt CM, Yurgil K, Risbrough V. Conditioned fear and extinction learning performance and its association with psychiatric symptoms in active duty Marines. Psychoneuroendocrinology. 2015 Jan; 51:495-505. PMID: 25444643.
        View in: PubMed
      23. Marshall AJ, Acheson DT, Risbrough V, Straus LD, Drummond SP. Fear conditioning, safety learning, and sleep in humans. J Neurosci. 2014 Aug 27; 34(35):11754-60. PMID: 25164670.
        View in: PubMed
      24. Huang MX, Yurgil KA, Robb A, Angeles A, Diwakar M, Risbrough V, Nichols SL, McLay R, Theilmann RJ, Song T, Huang CW, Lee RR, Baker DG. Voxel-wise resting-state MEG source magnitude imaging study reveals neurocircuitry abnormality in active-duty service members and veterans with PTSD. Neuroimage Clin. 2014; 5:408-19. PMID: 25180160.
        View in: PubMed
      25. Naviaux JC, Schuchbauer MA, Li K, Wang L, Risbrough V, Powell SB, Naviaux RK. Reversal of autism-like behaviors and metabolism in adult mice with single-dose antipurinergic therapy. Transl Psychiatry. 2014; 4:e400. PMID: 24937094.
        View in: PubMed
      26. Huang MX, Nichols S, Baker DG, Robb A, Angeles A, Yurgil KA, Drake A, Levy M, Song T, McLay R, Theilmann RJ, Diwakar M, Risbrough V, Ji Z, Huang CW, Chang DG, Harrington DL, Muzzatti L, Canive JM, Christopher Edgar J, Chen YH, Lee RR. Single-subject-based whole-brain MEG slow-wave imaging approach for detecting abnormality in patients with mild traumatic brain injury. Neuroimage Clin. 2014; 5:109-19. PMID: 25009772.
        View in: PubMed
      27. Minassian A, Geyer MA, Baker DG, Nievergelt CM, O'Connor DT, Risbrough V. Heart rate variability characteristics in a large group of active-duty marines and relationship to posttraumatic stress. Psychosom Med. 2014 May; 76(4):292-301. PMID: 24804881.
        View in: PubMed
      28. Schilling JM, Cui W, Godoy JC, Risbrough V, Niesman IR, Roth DM, Patel PM, Drummond JC, Patel HH, Zemljic-Harpf AE, Head BP. Long-term atorvastatin treatment leads to alterations in behavior, cognition, and hippocampal biochemistry. Behav Brain Res. 2014 Jul 1; 267:6-11. PMID: 24657594.
        View in: PubMed
      29. Risbrough V, Ji B, Hauger R, Zhou X. Generation and Characterization of Humanized Mice Carrying COMT158 Met/Val Alleles. Neuropsychopharmacology. 2014 Jul; 39(8):1823-32. PMID: 24509724.
        View in: PubMed
      30. Acheson DT, Geyer MA, Risbrough V. Psychophysiology in the study of psychological trauma: where are we now and where do we need to be? Curr Top Behav Neurosci. 2014; 21:157-83. PMID: 25158622.
        View in: PubMed
      31. Gresack JE, Seymour PA, Schmidt CJ, Risbrough V. Inhibition of phosphodiesterase 10A has differential effects on dopamine D1 and D2 receptor modulation of sensorimotor gating. Psychopharmacology (Berl). 2014 May; 231(10):2189-97. PMID: 24363077.
        View in: PubMed
      32. van Enkhuizen J, Acheson D, Risbrough V, Drummond S, Geyer MA, Young JW. Sleep deprivation impairs performance in the 5-choice continuous performance test: Similarities between humans and mice. Behav Brain Res. 2014 Mar 15; 261:40-8. PMID: 24333377.
        View in: PubMed
      33. Toth M, Gresack JE, Bangasser DA, Plona Z, Valentino RJ, Flandreau EI, Mansuy IM, Merlo-Pich E, Geyer MA, Risbrough V. Forebrain-Specific CRF Overproduction During Development is Sufficient to Induce Enduring Anxiety and Startle Abnormalities in Adult Mice. Neuropsychopharmacology. 2014 May; 39(6):1409-19. PMID: 24326400.
        View in: PubMed
      34. Toth M, Gresack JE, Hauger RL, Halberstadt AL, Risbrough V. The role of PKC signaling in CRF-induced modulation of startle. Psychopharmacology (Berl). 2013 Oct; 229(4):579-89. PMID: 23722830.
        View in: PubMed
      35. Acheson D, Feifel D, de Wilde S, McKinney R, Lohr J, Risbrough V. The effect of intranasal oxytocin treatment on conditioned fear extinction and recall in a healthy human sample. Psychopharmacology (Berl). 2013 Sep; 229(1):199-208. PMID: 23644911.
        View in: PubMed
      36. Liu X, Hong SI, Park SJ, Dela Peña JB, Che H, Yoon SY, Kim DH, Kim JM, Cai M, Risbrough V, Geyer MA, Shin CY, Cheong JH, Park H, Lew JH, Ryu JH. The ameliorating effects of 5,7-dihydroxy-6-methoxy-2(4-phenoxyphenyl)-4H-chromene-4-one, an oroxylin A derivative, against memory impairment and sensorimotor gating deficit in mice. Arch Pharm Res. 2013 Jul; 36(7):854-63. PMID: 23543630.
        View in: PubMed
      37. Tatro ET, Risbrough V, Soontornniyomkij B, Young J, Shumaker-Armstrong S, Jeste DV, Achim CL. Short-term recognition memory correlates with regional CNS expression of microRNA-138 in mice. Am J Geriatr Psychiatry. 2013 May; 21(5):461-73. PMID: 23570889.
        View in: PubMed
      38. Toth M, Ziegler M, Sun P, Gresack J, Risbrough V. Impaired conditioned fear response and startle reactivity in epinephrine-deficient mice. Behav Pharmacol. 2013 Feb; 24(1):1-9. PMID: 23268986.
        View in: PubMed
      39. Li X, Risbrough V, Cates-Gatto C, Kaczanowska K, Finn MG, Roberts AJ, Markou A. Comparison of the effects of the GABAB receptor positive modulator BHF177 and the GABAB receptor agonist baclofen on anxiety-like behavior, learning, and memory in mice. Neuropharmacology. 2013 Jul; 70:156-67. PMID: 23376712.
        View in: PubMed
      40. Bomyea J, Risbrough V, Lang AJ. A consideration of select pre-trauma factors as key vulnerabilities in PTSD. Clin Psychol Rev. 2012 Nov; 32(7):630-41. PMID: 22917742.
        View in: PubMed
      41. Acheson DT, Stein MB, Paulus MP, Ravindran L, Simmons AN, Lohr JB, Risbrough V. Effects of anxiolytic treatment on potentiated startle during aversive image anticipation. Hum Psychopharmacol. 2012 Jul; 27(4):419-27. PMID: 22782542.
        View in: PubMed
      42. Baker DG, Nash WP, Litz BT, Geyer MA, Risbrough V, Nievergelt CM, O'Connor DT, Larson GE, Schork NJ, Vasterling JJ, Hammer PS, Webb-Murphy JA. Predictors of risk and resilience for posttraumatic stress disorder among ground combat Marines: methods of the Marine Resiliency Study. Prev Chronic Dis. 2012; 9:E97. PMID: 22575082.
        View in: PubMed
      43. Acheson DT, Stein MB, Paulus MP, Geyer MA, Risbrough V. The effect of pregabalin on sensorimotor gating in 'low' gating humans and mice. Neuropharmacology. 2012 Sep; 63(3):480-5. PMID: 22575075.
        View in: PubMed
      44. Soontornniyomkij V, Risbrough V, Young JW, Soontornniyomkij B, Jeste DV, Achim CL. Hippocampal calbindin-1 immunoreactivity correlate of recognition memory performance in aged mice. Neurosci Lett. 2012 May 10; 516(1):161-5. PMID: 22503902.
        View in: PubMed
      45. Hellgren C, Bannbers E, Åkerud H, Risbrough V, Poromaa IS. Decreased startle modulation during anticipation in the postpartum period in comparison to late pregnancy. Arch Womens Ment Health. 2012 Apr; 15(2):87-94. PMID: 22315106.
        View in: PubMed
      46. Ahmari SE, Risbrough V, Geyer MA, Simpson HB. Impaired sensorimotor gating in unmedicated adults with obsessive-compulsive disorder. Neuropsychopharmacology. 2012 Apr; 37(5):1216-23. PMID: 22218093.
        View in: PubMed
      47. Risbrough V, Stein MB. Neuropharmacology special issue on posttraumatic stress disorder (PTSD): current state of the art in clinical and preclinical PTSD research. Neuropharmacology. 2012 Feb; 62(2):539-41. PMID: 21875608.
        View in: PubMed
      48. Tanaka S, Young JW, Gresack JE, Geyer MA, Risbrough V. Factor analysis of attentional set-shifting performance in young and aged mice. Behav Brain Funct. 2011; 7:33. PMID: 21838910.
        View in: PubMed
      49. Steckler T, Risbrough V. Pharmacological treatment of PTSD - established and new approaches. Neuropharmacology. 2012 Feb; 62(2):617-27. PMID: 21736888.
        View in: PubMed
      50. Acheson DT, Gresack JE, Risbrough V. Hippocampal dysfunction effects on context memory: possible etiology for posttraumatic stress disorder. Neuropharmacology. 2012 Feb; 62(2):674-85. PMID: 21596050.
        View in: PubMed
      51. van den Buuse M, Ruimschotel E, Martin S, Risbrough V, Halberstadt AL. Enhanced effects of amphetamine but reduced effects of the hallucinogen, 5-MeO-DMT, on locomotor activity in 5-HT(1A) receptor knockout mice: implications for schizophrenia. Neuropharmacology. 2011 Jul-Aug; 61(1-2):209-16. PMID: 21501627.
        View in: PubMed
      52. Soontornniyomkij V, Risbrough V, Young JW, Soontornniyomkij B, Jeste DV, Achim CL. Increased hippocampal accumulation of autophagosomes predicts short-term recognition memory impairment in aged mice. Age (Dordr). 2012 Apr; 34(2):305-16. PMID: 21431350.
        View in: PubMed
      53. Bannbers E, Kask K, Wikström J, Risbrough V, Poromaa IS. Patients with premenstrual dysphoric disorder have increased startle modulation during anticipation in the late luteal phase period in comparison to control subjects. Psychoneuroendocrinology. 2011 Sep; 36(8):1184-92. PMID: 21435793.
        View in: PubMed
      54. van den Buuse M, Becker T, Kwek P, Martin S, Ruimschotel E, Risbrough V. Disruption of prepulse inhibition by 3,4-methylenedioxymethamphetamine (MDMA): comparison between male and female wild-type and 5-HT(1A) receptor knockout mice. Int J Neuropsychopharmacol. 2011 Jul; 14(6):856-61. PMID: 21329554.
        View in: PubMed
      55. Gresack JE, Risbrough V. Corticotropin-releasing factor and noradrenergic signalling exert reciprocal control over startle reactivity. Int J Neuropsychopharmacol. 2011 Oct; 14(9):1179-94. PMID: 21205416.
        View in: PubMed
      56. Ali SS, Young JW, Wallace CK, Gresack J, Jeste DV, Geyer MA, Dugan LL, Risbrough V. Initial evidence linking synaptic superoxide production with poor short-term memory in aged mice. Brain Res. 2011 Jan 12; 1368:65-70. PMID: 21075081.
        View in: PubMed
      57. Winn ME, Zapala MA, Hovatta I, Risbrough V, Lillie E, Schork NJ. The effects of globin on microarray-based gene expression analysis of mouse blood. Mamm Genome. 2010 Jun; 21(5-6):268-75. PMID: 20473674.
        View in: PubMed
      58. Gresack J, Powell S, Geyer M, Poore MS, Coste S, Risbrough V. CRF2 null mutation increases sensitivity to isolation rearing effects on locomotor activity in mice. Neuropeptides. 2010 Aug; 44(4):349-53. PMID: 20466421.
        View in: PubMed
      59. Young JW, Powell SB, Geyer MA, Jeste DV, Risbrough V. The mouse attentional-set-shifting task: a method for assaying successful cognitive aging? Cogn Affect Behav Neurosci. 2010 May; 10(2):243-51. PMID: 20498348.
        View in: PubMed
      60. Soontornniyomkij V, Risbrough V, Young JW, Wallace CK, Soontornniyomkij B, Jeste DV, Achim CL. Short-term recognition memory impairment is associated with decreased expression of FK506 binding protein 51 in the aged mouse brain. Age (Dordr). 2010 Sep; 32(3):309-22. PMID: 20422297.
        View in: PubMed
      61. Young JW, Wallace CK, Geyer MA, Risbrough V. Age-associated improvements in cross-modal prepulse inhibition in mice. Behav Neurosci. 2010 Feb; 124(1):133-40. PMID: 20141288.
        View in: PubMed
      62. Gresack JE, Risbrough V, Scott CN, Coste S, Stenzel-Poore M, Geyer MA, Powell SB. Isolation rearing-induced deficits in contextual fear learning do not require CRF(2) receptors. Behav Brain Res. 2010 May 1; 209(1):80-4. PMID: 20097235.
        View in: PubMed
      63. Risbrough V. Behavioral correlates of anxiety. Curr Top Behav Neurosci. 2010; 2:205-28. PMID: 21309111.
        View in: PubMed
      64. Hauger RL, Risbrough V, Oakley RH, Olivares-Reyes JA, Dautzenberg FM. Role of CRF receptor signaling in stress vulnerability, anxiety, and depression. Ann N Y Acad Sci. 2009 Oct; 1179:120-43. PMID: 19906236.
        View in: PubMed
      65. Adamec R, Fougere D, Risbrough V. CRF receptor blockade prevents initiation and consolidation of stress effects on affect in the predator stress model of PTSD. Int J Neuropsychopharmacol. 2010 Jul; 13(6):747-57. PMID: 19751543.
        View in: PubMed
      66. Baker DG, Nievergelt CM, Risbrough V. Post-traumatic stress disorder: emerging concepts of pharmacotherapy. Expert Opin Emerg Drugs. 2009 Jun; 14(2):251-72. PMID: 19453285.
        View in: PubMed
      67. Duvvuri V, Risbrough V, Kaye WH, Geyer MA. 5-HT1A receptor activation is necessary for 5-MeODMT-dependent potentiation of feeding inhibition. Pharmacol Biochem Behav. 2009 Sep; 93(3):349-53. PMID: 19490926.
        View in: PubMed
      68. Halberstadt AL, van der Heijden I, Ruderman MA, Risbrough V, Gingrich JA, Geyer MA, Powell SB. 5-HT(2A) and 5-HT(2C) receptors exert opposing effects on locomotor activity in mice. Neuropsychopharmacology. 2009 Jul; 34(8):1958-67. PMID: 19322172.
        View in: PubMed
      69. Young JW, Powell SB, Risbrough V, Marston HM, Geyer MA. Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol Ther. 2009 May; 122(2):150-202. PMID: 19269307.
        View in: PubMed
      70. Risbrough V, Geyer MA, Hauger RL, Coste S, Stenzel-Poore M, Wurst W, Holsboer F. CRF1 and CRF2 receptors are required for potentiated startle to contextual but not discrete cues. Neuropsychopharmacology. 2009 May; 34(6):1494-503. PMID: 19020499.
        View in: PubMed
      71. Halberstadt AL, Buell MR, Masten VL, Risbrough V, Geyer MA. Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors. Psychopharmacology (Berl). 2008 Nov; 201(1):55-66. PMID: 18604652.
        View in: PubMed
      72. Jonkman S, Risbrough V, Geyer MA, Markou A. Spontaneous nicotine withdrawal potentiates the effects of stress in rats. Neuropsychopharmacology. 2008 Aug; 33(9):2131-8. PMID: 18033237.
        View in: PubMed
      73. Ponder CA, Kliethermes CL, Drew MR, Muller J, Das K, Risbrough V, Crabbe JC, Gilliam TC, Palmer AA. Selection for contextual fear conditioning affects anxiety-like behaviors and gene expression. Genes Brain Behav. 2007 Nov; 6(8):736-49. PMID: 17309658.
        View in: PubMed
      74. Vinkers CH, Risbrough V, Geyer MA, Caldwell S, Low MJ, Hauger RL. Role of dopamine D1 and D2 receptors in CRF-induced disruption of sensorimotor gating. Pharmacol Biochem Behav. 2007 Mar; 86(3):550-8. PMID: 17324452.
        View in: PubMed
      75. Hauger RL, Risbrough V, Brauns O, Dautzenberg FM. Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets. CNS Neurol Disord Drug Targets. 2006 Aug; 5(4):453-79. PMID: 16918397.
        View in: PubMed
      76. Risbrough V, Stein MB. Role of corticotropin releasing factor in anxiety disorders: a translational research perspective. Horm Behav. 2006 Nov; 50(4):550-61. PMID: 16870185.
        View in: PubMed
      77. Risbrough V, Masten VL, Caldwell S, Paulus MP, Low MJ, Geyer MA. Differential contributions of dopamine D1, D2, and D3 receptors to MDMA-induced effects on locomotor behavior patterns in mice. Neuropsychopharmacology. 2006 Nov; 31(11):2349-58. PMID: 16855533.
        View in: PubMed
      78. Risbrough V, Geyer MA. Anxiogenic treatments do not increase fear-potentiated startle in mice. Biol Psychiatry. 2005 Jan 1; 57(1):33-43. PMID: 15607298.
        View in: PubMed
      79. Risbrough V, Hauger RL, Roberts AL, Vale WW, Geyer MA. Corticotropin-releasing factor receptors CRF1 and CRF2 exert both additive and opposing influences on defensive startle behavior. J Neurosci. 2004 Jul 21; 24(29):6545-52. PMID: 15269266.
        View in: PubMed
      80. Risbrough V, Hauger RL, Pelleymounter MA, Geyer MA. Role of corticotropin releasing factor (CRF) receptors 1 and 2 in CRF-potentiated acoustic startle in mice. Psychopharmacology (Berl). 2003 Nov; 170(2):178-87. PMID: 12845406.
        View in: PubMed
      81. Bontempi B, Whelan KT, Risbrough V, Lloyd GK, Menzaghi F. Cognitive enhancing properties and tolerability of cholinergic agents in mice: a comparative study of nicotine, donepezil, and SIB-1553A, a subtype-selective ligand for nicotinic acetylcholine receptors. Neuropsychopharmacology. 2003 Jul; 28(7):1235-46. PMID: 12700710.
        View in: PubMed
      82. Risbrough V, Brodkin JD, Geyer MA. GABA-A and 5-HT1A receptor agonists block expression of fear-potentiated startle in mice. Neuropsychopharmacology. 2003 Apr; 28(4):654-63. PMID: 12655310.
        View in: PubMed
      83. Risbrough V, Bontempi B, Menzaghi F. Selective immunolesioning of the basal forebrain cholinergic neurons in rats: effect on attention using the 5-choice serial reaction time task. Psychopharmacology (Berl). 2002 Oct; 164(1):71-81. PMID: 12373421.
        View in: PubMed
      84. Terry AV, Risbrough V, Buccafusco JJ, Menzaghi F. Effects of (+/-)-4-[[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride (SIB-1553A), a selective ligand for nicotinic acetylcholine receptors, in tests of visual attention and distractibility in rats and monkeys. J Pharmacol Exp Ther. 2002 Apr; 301(1):284-92. PMID: 11907185.
        View in: PubMed
      85. Bontempi B, Whelan KT, Risbrough V, Rao TS, Buccafusco JJ, Lloyd GK, Menzaghi F. SIB-1553A, (+/-)-4-[[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride, a subtype-selective ligand for nicotinic acetylcholine receptors with putative cognitive-enhancing properties: effects on working and reference memory performances in aged rodents and nonhuman primates. J Pharmacol Exp Ther. 2001 Oct; 299(1):297-306. PMID: 11561092.
        View in: PubMed
      86. Schulteis G, Stinus L, Risbrough V, Koob GF. Clonidine blocks acquisition but not expression of conditioned opiate withdrawal in rats. Neuropsychopharmacology. 1998 Nov; 19(5):406-16. PMID: 9778662.
        View in: PubMed
      87. Schulteis G, Yackey M, Risbrough V, Koob GF. Anxiogenic-like effects of spontaneous and naloxone-precipitated opiate withdrawal in the elevated plus-maze. Pharmacol Biochem Behav. 1998 Jul; 60(3):727-31. PMID: 9678657.
        View in: PubMed
      88. Menzaghi F, Whelan KT, Risbrough V, Rao TS, Lloyd GK. Effects of a novel cholinergic ion channel agonist SIB-1765F on locomotor activity in rats. J Pharmacol Exp Ther. 1997 Jan; 280(1):384-92. PMID: 8996219.
        View in: PubMed
      89. Menzaghi F, Whelan KT, Risbrough V, Rao TS, Lloyd GK. Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats. J Pharmacol Exp Ther. 1997 Jan; 280(1):393-401. PMID: 8996220.
        View in: PubMed
      Victoria's Networks
      Concepts
      Derived automatically from this person's publications.
      _
      Co-Authors
      People in Profiles who have published with this person.
      _
      Similar People
      People who share similar concepts with this person.
      _
      Same Department
      Physical Neighbors
      People whose addresses are nearby this person.
      _